Novavax Stock Crosses 200-Day Moving Average

Shares of the biotech company rise as analysts weigh in on its prospects

Mar. 31, 2026 at 6:11am

Got story updates? Submit your updates here. ›

An extreme close-up of the inner workings of a pharmaceutical manufacturing plant, with a maze of metal pipes, valves, and industrial components filling the frame, conceptually representing the complex financial and technological infrastructure behind vaccine development.The heavy machinery and precision engineering behind Novavax's vaccine production highlight the significant financial and technological resources required for biotech innovation.Gaithersburg Today

Shares of Novavax, Inc. (NASDAQ:NVAX) crossed above their 200-day moving average on Monday, trading as high as $8.42 before closing at $8.09. The biopharmaceutical company's stock has seen increased trading volume as analysts provide updated ratings and price targets.

Why it matters

Crossing above the 200-day moving average is often seen as a bullish technical indicator, signaling potential momentum for the stock. Novavax's share price has been volatile in recent months as the company continues development of its COVID-19 vaccine candidate.

The details

Novavax's stock price has fluctuated between $6.38 and $10.84 over the past 52 weeks. The company recently reported Q4 2025 earnings, posting a surprise profit of $0.11 per share compared to an expected loss of $0.66 per share. Revenue for the quarter came in at $136.4 million, up 66.6% year-over-year.

  • Novavax's stock crossed above its 200-day moving average of $8.28 on Monday, March 30, 2026.
  • The company reported Q4 2025 earnings on Thursday, February 27, 2026.

The players

Novavax, Inc.

A clinical-stage biotechnology company that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases.

BTIG Research

An equity research firm that covers Novavax and has a "buy" rating on the stock.

Weiss Ratings

A financial research firm that recently upgraded its rating on Novavax from "sell" to "hold".

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

What’s next

Analysts will continue to monitor Novavax's progress with its COVID-19 vaccine candidate and provide updates on the company's outlook.

The takeaway

Novavax's stock price movement reflects the volatility and uncertainty surrounding the biotech industry, particularly as companies race to develop effective vaccines and treatments for the ongoing pandemic.